Enterprise Financial Services Corp (EFSC)’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,620
Closed -$5K 1391
2020
Q3
$5K Buy
+1,620
New +$5.17K ﹤0.01% 867
2017
Q1
Sell
-8,573
Closed -$18K 1131
2016
Q4
$18K Buy
8,573
+959
+13% +$2.68K 0.01% 473
2016
Q3
$26K Hold
7,614
0.01% 371
2016
Q2
$24K Hold
7,614
0.01% 365
2016
Q1
$25K Buy
+7,614
New +$23.7K 0.02% 356
2015
Q4
Sell
-3,768
Closed -$19K 1203
2015
Q3
$19K Sell
3,768
-1,903
-34% -$10.9K 0.01% 407
2015
Q2
$36K Buy
5,671
+2,518
+80% +$16.9K 0.02% 296
2015
Q1
$22K Sell
3,153
-564
-15% -$4.08K 0.01% 415
2014
Q4
$29K Sell
3,717
-3,444
-48% -$27.3K 0.02% 357
2014
Q3
$53K Buy
7,161
+3,118
+77% +$28.9K 0.03% 249
2014
Q2
$39K Hold
4,043
0.02% 312
2014
Q1
$34K Buy
4,043
+3,966
+5,151% +$34K 0.02% 319
2013
Q4
$1K Buy
+77
New +$649 ﹤0.01% 1208

Other funds holding PDLI

Enterprise Financial Services Corp (EFSC)'s PDLI Position: Q4 2020 in Review

Enterprise Financial Services Corp (EFSC) sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 1,620 shares — an estimated $5K sold.

Enterprise Financial Services Corp (EFSC) first reported a position in PDLI in Q4 2013 and held it in 13 quarters. The position peaked at $53K in Q3 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Enterprise Financial Services Corp (EFSC) reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Enterprise Financial Services Corp (EFSC) sold 1,620 PDL BioPharma, Inc. shares in Q4 2020, an estimated $5K.
  • Enterprise Financial Services Corp (EFSC) first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 13 quarters.
  • Enterprise Financial Services Corp (EFSC)'s PDL BioPharma, Inc. position peaked at $53K in Q3 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Enterprise Financial Services Corp (EFSC)'s 13F filing for Q4 2020, filed 12 Feb 2021.